BioWorld

Sep. 25, 2007

Adnexus Nixes IPO Route, Opts For $430M BMS Exit

Pharmaceutical giant Bristol-Myers Squibb Co. is acquiring Waltham-Mass.-based Adnexus Therapeutics Inc. for $430 million in an all-cash deal, the firms said Monday. (BioWorld Today) Read More

Celgene Paying Array $40M Up Front For Drug Discovery

Ariad Hoping To 'Succeed' In Phase III Study Of Deforolimus

Sonus Crashes On Failed Pivotal Trial Of Tocosol Paclitaxel Drug

Elixir Aiming For Public Markets With $86M IPO

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 25, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 25, 2025.

Moderna expands mRNA tech to latent viruses, cancer, rare disease

BioWorld

Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...

No vote, ACIP recurring theme at CDC confirmation hearing

BioWorld

Although the U.S. CDC’s Advisory Committee for Immunization Practices (ACIP) was scheduled to vote June 25 on recommendations for maternal and pediatric...

Revmed goes global with $2B in capital for RAS(ON) inhibitors

BioWorld

Taking an unconventional path to market for its targeted therapies for RAS-addicted cancers, Revolution Medicines Inc. secured access to $2 billion in capital to...